The Difference in Mortality, Seroconversion, and Duration of Hospitalization Between Patients With and Without Anti-CD20 Antibody Therapy Among Hematological Malignancies With Superadded COVID-19 Infection

Vegivinti, Charan Thej Reddy and Thakur, Rahul and Shivakumar, Jeevan and Hammami, M. Bakri and Mehta, Mansi and Santhi, Jaison Lawrence Alexander and Pappoppula, Lakshmi and Elango, Pranesh Siruvalur and Kakumani, Venkata Kiranmayi and Gudi, Thulasi Ram and Gopireddy, Murali Mohan Reddy and Poojary, Nagarathna and Ghimire, Ananta and Kesari, Praneeth Reddy and Chintapally, Nikita and Musunuru, Tejo Niharika (2023) The Difference in Mortality, Seroconversion, and Duration of Hospitalization Between Patients With and Without Anti-CD20 Antibody Therapy Among Hematological Malignancies With Superadded COVID-19 Infection. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 23.0. S440-S441. ISSN 2152-2650

Full text not available from this repository.
Item Type: Article
Uncontrolled Keywords: aggressive B-cell lymphoma, COVID-19, anti-CD20, hematologic malignancy, mortality, lymphoma
Depositing User: Unnamed user with email techsupport@mosys.org
Date Deposited: 17 Feb 2026 09:18
Last Modified: 17 Feb 2026 09:18
URI: https://ir.vmrfdu.edu.in/id/eprint/7554

Actions (login required)

View Item
View Item